Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Anil Sedani"'
Autor:
Karina Galoian, Victoria Dahl, Andres Perez, Carina Denny, Beatrice Becker, Anil Sedani, Alexandra Moran, Daniel Martinez, Aaron Hoyt, Jeffrey Brown
Publikováno v:
Cancer Treatment and Research Communications, Vol 33, Iss , Pp 100644- (2022)
Background: Previous studies showed that proline-rich polypeptide (PRP-1) is a ligand for innate immunity toll-like receptors (TLR), and an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1) which induces the death of chondrosarcoma ca
Externí odkaz:
https://doaj.org/article/2825b92533994940a1f16f292c7cdc1d
Autor:
Ramakanth R. Yakkanti, Anil Sedani, Dylan N. Greif, Rukmini Yakkanti, Dustin H. Massel, Victor H. Hernandez
Publikováno v:
Advances in Orthopedics, Vol 2022 (2022)
Introduction. The direct anterior approach (DAA) has garnered a lot of attention and surgical popularity for total hip arthroplasty in recent years. Some of the postulated advantages for the increase in popularity of this approach include better pain
Externí odkaz:
https://doaj.org/article/30d807fcc6f644ef85d4b08efd67b895
Publikováno v:
J Clin Orthop Trauma
Purpose One of the most common adverse events after orthopaedic surgery, with a potential for subsequent serious morbidity and mortality is venous thromboembolism (VTE). Bibliometric analysis has been performed regarding many topics and across orthop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeafd00225cbab25acfa09829d0d176f
https://doi.org/10.1016/j.jcot.2020.12.015
https://doi.org/10.1016/j.jcot.2020.12.015
Autor:
Alexandra Moran, Caroline J. Granger, Anil Sedani, Shannon Saigh, Beatrice Becker, Sheila A. Conway, Jeffrey Brown, Karina Galoian, Aaron K. Hoyt
Publikováno v:
Molecular Medicine Reports
Chondrosarcoma is a malignant bone neoplasm that is refractory to chemotherapy and radiation. With no current biological treatments, mutilating surgical resection is the only effective treatment. Proline rich polypeptide 1 (PRP‑1), which is a 15‑
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f9aba43e297dc04382d535cf5839193
http://europepmc.org/articles/PMC7533489
http://europepmc.org/articles/PMC7533489
Autor:
Caroline J. Granger, Liu Zhao-Ju, Sheila A. Conway, Jeffrey Brown, Anil Sedani, Karina Galoian, Aaron K. Hoyt, Juan Pretell, Shannon Saigh, Marzenna Blonska, Alexandra Moran
Publikováno v:
Oncology Reports. 44:393-403
Chondrosarcoma is the second most common primary malignant bone tumor and is resistant to chemotherapy and radiation. Inadequate treatment response and poor prognosis requires novel therapeutic approaches. Proline‑rich polypeptide‑1 (PRP‑1), sy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25864ad7828719c4695db6cfc74ce99b
https://doi.org/10.3892/or.2020.7612
https://doi.org/10.3892/or.2020.7612
Autor:
Aaron K. Hoyt, Alexandra Moran, Anil Sedani, Karina Galoian, Jeffrey Brown, Shannon Saigh, Caroline J. Granger
Publikováno v:
Oncology Reports
Chondrosarcomas are malignant bone tumors refractory to chemotherapy and radiation treatment; thus, novel therapeutic strategies are required. Proline‑rich polypeptide 1 (PRP‑1) has previously demonstrated antitumor properties in chondrosarcoma.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::947e6a73c4d93c302914ed9805c5b069
http://europepmc.org/articles/PMC6549102
http://europepmc.org/articles/PMC6549102